GSK Pharma Q1 profit rises 16% as medicines and vaccines lift growth
GSK Pharma reported Q1 FY27 net profit of ₹237.1 crore, up 15.7% year-on-year, while revenue grew 16.6% to ₹938 crore. The company is preparing to launch Blenrep in India and commercially roll out RSV vaccine Arexvy following marketing authorisation.
GSK Pharma reported stronger Q1 FY27 profit, revenue and margins, driven by general medicines and vaccines. It is preparing to launch Blenrep in India, while RSV vaccine Arexvy has received marketing authorisation.
Why this matters
GSK Pharma's Q1 FY27 results reinforce the recent signal reporting profit growth to about ₹237 crore and revenue of ₹938 crore, while adding planned launches of Blenrep and Arexvy.
Retail-company signals are accelerating, up 228300% quarter-on-quarter.